Sodium adenosine triphosphate - description of the drug, instructions for use, reviews. Preparation for ATP injection: indications, contraindications and features of the use of sodium adenosine triphosphate

Dosage form:  solution for intravenous administration Composition:

1 ml of solution contains:

active substance: sodium adenosine triphosphate disubstituted 10.00 mg;

Excipients: sodium hydroxide solution 2M to pH 7.0 - 7.3, water for injection up to 1 ml.

 Description: Clear, colorless or slightly yellowish liquid. Pharmacotherapeutic group:metabolic agent ATX:  

C.01.E.B Other drugs for the treatment of heart disease

Pharmacodynamics:

Metabolic agent, has a hypotensive and antiarrhythmic effect, dilates the coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. Contained in many organs and tissues, but most of all - in the skeletal muscles.

Improves metabolism and energy supply of tissues. Splitting into ADP and inorganic phosphate, it releases a large amount of energy used for muscle contraction, protein synthesis, urea, intermediate metabolic products, etc. Later, the decay products are included in ATP resynthesis. Under the influence of triphosadenine, there is a decrease blood pressure and relaxation smooth muscle, the conduction of nerve impulses in the autonomic ganglia and the transmission of excitation from n.vagus to the heart improve, myocardial contractility increases. suppresses the automatism of the sinus-atrial node and Purkinje fibers (blockade of Ca 2+ channels and an increase in permeability to K +).

It is not possible to track the kinetics of a parenterally administered ATP preparation due to the high voltage of various reactions that occur with the participation of one's own ATP. However, it is known that sodium adenosine triphosphatequickly decomposes at the injection site into phosphate residues, which are subsequently used to synthesize new ATP molecules. Indications:

Relief of paroxysms of supraventricular tachycardia (excluding flicker and / or atrial flutter).

 Contraindications:

Hypersensitivity to the drug, acute myocardial infarction, severe arterial hypotension, severe bradycardia, weakness syndrome sinus node, atrioventricular block II-III degree (with the exception of patients with an artificial pacemaker), chronic obstructive pulmonary disease, bronchial asthma, long QT syndrome, acute and chronic heart failure in the stage of decompensation, pregnancy, lactation, age up to 18 years.

Children

There is no experience of using the drug in children (under 18 years of age).

 Carefully:

Bradycardia, atrioventricular block I degree, bundle branch block, atrial fibrillation and flutter, arterial hypotension, coronary heart disease, hypovolemia, pericarditis, valvular stenosis, left-to-right arteriovenous shunt, insufficiency cerebral circulation, conditions after heart transplantation (less than 1 year).

 Pregnancy and lactation:

Information regarding the use of the drug during pregnancy and breastfeeding missing.

 Dosage and administration:

The drug is administered intravenously quickly into the central or large peripheral vein, 3 mg for 2 seconds under the control of ECG and blood pressure; if necessary, after 1-2 minutes, 6 mg is re-introduced, after 1-2 minutes - 12 mg.

Treatment is stopped with the development of AV blockade at any of the stages of administration.

 Side effects:

Development frequency side effects classified according to the recommendations of the World Health Organization: very often - more than 1/10; often - more than 1/100 and less than 1/10; infrequently - more than 1/1000 and less than 1/100; rarely - more than 1/10000 and less than 1/1000; very rarely - more than 1/10000; frequency not established (frequency cannot be estimated from available data).

From the side of the cardiovascular system: very often - flushing of blood to the skin of the face, a feeling of discomfort in chest(feeling of "pressure", pain), bradycardia, sinus arrest, atrioventricular block, various atrial and ventricular extrasystoles, ventricular tachycardia; infrequently - sinus tachycardia, palpitations; very rarely - atrial fibrillation, severe bradycardia not stopped by the introduction of atropine and requiring the setting of an artificial pacemaker, ventricular fibrillation, tachycardia of the "pirouette" type; the frequency has not been established - a pronounced decrease in blood pressure, asystole / cardiac arrest, sometimes fatal (in patients with coronary heart disease).

From the side of the central nervous system : often - headache, dizziness, various phobias; infrequently - a feeling of "pressure" in the head; very rarely - transientincreased intracranial pressure; frequency not established - loss of consciousness / fainting, convulsions.

From the organ of vision: infrequently - visual impairment.

From the side respiratory system : very often - shortness of breath; infrequently - rapid breathing; very rarely - bronchospasm; frequency not established - respiratory failure, apnea / respiratory arrest.

From the gastrointestinal tract: often - nausea; infrequently - a metallic taste in the mouth; frequency not established - vomiting.

Other: infrequently - increased sweating, weakness; very rarely - reactions at the injection site (tingling sensation).

 Overdose:

Symptoms: may be manifested by dizziness, arterial hypotension, short-term loss of consciousness, arrhythmia.

Treatment : the introduction of the drug is immediately stopped (due to the short half-life, side effects quickly pass). If necessary, it is possible to introduce xanthines ( , ), which are competitive antagonists of triphosadenine and reduce its effect.

 Interaction:

Dipyridamole - enhances the action of triphosadenine, in some cases up to asystole, so the simultaneous administration of drugs is not recommended. If it is necessary to administer triphosadenine, it is necessary to stop treatment with dipyridamole 24 hours before the administration of triphosadenine or reduce its dose.

Purine derivatives (coffeine and) and xanthinol nicotinate - and other xanthines are competitive antagonists of triphosadenine, their use should be avoided within 24 hours before the administration of triphosadenine.

Xanthine-containing products (including tea, coffee, chocolate) should not be consumed 12 hours before the administration of the drug.

Carbamazepine may increase the inhibitory effect of triphosadenine on atrioventricular conduction, which can lead to complete atrioventricular block

You can not enter simultaneously with cardiac glycosides in large doses, as the risk of adverse reactions from the cardiovascular system increases.

 Special instructions:

The introduction of the drug, as a rule, should be carried out only intravenously under medical supervision, while monitoring heart function and blood pressure.

Due to the risk of arterial hypotension, the drug should be used with caution in patients with coronary heart disease, hypovolemia, pericarditis, valvular stenosis, left-to-right arteriovenous shunt, cerebrovascular insufficiency. Sodium adenosine triphosphate-Darnitsa should be used with caution in patients with recent myocardial infarction, with severe chronic heart failure, impaired conduction system of the heart (atrioventricular block I degree, bundle branch block) due to the possibility of their aggravation with the introduction of the drug. With the development of angina pectoris, severe bradycardia, arterial hypotension, respiratory failure or asystole / cardiac arrest, the drug should be discontinued. The drug can cause convulsions in predisposed patients (convulsions in history of various origins).

Previously, the drug was used for the following indications (at present, due to low efficacy, the following indications are excluded): muscular dystrophy and atrophy, poliomyelitis, multiple sclerosis, coronary insufficiency, postinfarction cardiomyodystrophy, acute and chronic cardiovascular insufficiency, obliterating diseases of the arteries - "intermittent " lameness, Raynaud's disease, thromboangiitis obliterans (Buerger's disease), hereditary pigmentary retinal degeneration, weakness of labor activity.

 Influence on the ability to drive transport. cf. and fur.:The effect of the drug on the ability to drive vehicles and other mechanisms has not been studied. Release form / dosage:Solution for intravenous administration. Package:

1 ml in an ampoule.

It is allowed to stick a label made of paper with a self-adhesive coating on the ampoule.

5 ampoules with a knife for opening ampoules or an ampoule scarifier in a blister pack (cassette).

Two blister packs with instructions for medical use in a pack.

By10 ampoules with a knife for opening ampoules or an ampoule scarifier in a blister pack(cassette).By1 contourcell packaging with instructions for medical application in a pack. 10 ampoules with instructions for medical application, a knife for opening ampoules or an ampoule scarifierin a box with a corrugated liner. The box is pasted over with a label-package.

When packing ampoules with a colored break ringor breaking pointa knife for opening ampoules or an ampoule scarifier is not included.

 Storage conditions:

Store in original packaging at temperatures between 2°C and 8°C.

Keep out of the reach of children.

 Best before date:

Do not use after the expiry date stated on the packaging.

 Conditions for dispensing from pharmacies: On prescription Registration number: P N010635 Date of registration: 25.04.2012 / 25.04.2013 Expiration date: Perpetual Registration certificate holder:DARNITSA PHARMACEUTICAL FIRM, CJSC Ukraine Manufacturer:   Information update date:   26.05.2018 Illustrated Instructions

Active substance: adenosine triphosphoric acid - 10 mg.
Excipients: sodium hydroxide solution 2 M (up to pH 7.0-7.3), water for injection.

Indications for use Sodium adenosine triphosphate

Relief of paroxysms of supraventricular tachycardia (excluding flicker and / or atrial flutter).

Contraindications to the use of sodium adenosine triphosphate

Hypersensitivity, acute myocardial infarction, arterial hypotension, inflammatory lung diseases.

The drug is administered intravenously quickly into the central or large peripheral vein 3 mg for 2 seconds under the control of the electrocardiogram and blood pressure; if necessary, after 1-2 minutes, 6 mg of the drug is re-introduced, after 1-2 minutes. 12 mg; the introduction is stopped with the development of atrioventricular blockade at any of the stages of drug administration.

pharmachologic effect

Sodium adenosine triphosphate (ATP) is a metabolic agent, has an antiarrhythmic effect, also has a hypotensive effect, dilates the coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. Contained in many organs and tissues, but most of all - in the skeletal muscles. Improves metabolism and energy supply of tissues. Due to its splitting into ADP and inorganic phosphate, ATP releases a large amount of energy used for muscle contraction, protein synthesis, urea, metabolic intermediates, etc. Under the influence of ATP, blood pressure decreases and smooth muscles relax, and nerve impulses in the autonomic ganglia improve and transfer of excitation from vagus nerve on the heart, myocardial contractility increases. After parenteral administration, it penetrates into the cells of organs, where it is cleaved into adenosine and inorganic phosphate with the release of energy. In the future, the cleavage products are included in the resynthesis of ATP. The antiarrhythmic effect is due to the adenosine formed during the breakdown of ATP, which suppresses the automatism of the sinoatrial node and Purkinje fibers (blockade of calcium channels and an increase in permeability to potassium ions).

Side effects of sodium adenosine triphosphate

Possible allergic reactions(itching, flushing of the skin), nausea, flushing of the skin of the face, headache, weakness; after stopping the paroxysm of tachycardia, short-term episodes of sinus bradycardia and / or atrioventricular block I-III degree may be observed (ECG control).

special instructions

Do not administer large doses simultaneously with cardiac glycosides.

Overdose

Due to the short half-life, adverse events quickly disappear. Competitive antagonists are theophylline and other methylxanthines.

drug interaction

Cardiac glycosides increase the risk of side effects (including arrhythmogenic effects). Dipyridamole enhances the effect; theophylline, caffeine and other methylxanthines - weaken.

Storage conditions

In a place protected from light, at a temperature of (5 ± 2) ° С. Keep out of the reach of children. Expiration date - 1 year.

25.02.2012 9250

ATP (sodium adenosine triphosphate). Description, instruction.

Supraventricular paroxysmal tachycardia (paroxysm relief). Previously, the drug was used for the following indications (currently, due to low efficacy, the following indications are excluded): muscular dystrophy and atrophy, poliomyelitis, multiple sclerosis ...

International name:
Triphosadenine (Triphosadenine)

Description active substance(INN):
Trifosadenine

Dosage form:
lyophilisate for solution for intravenous administration, solution for intravenous administration

pharmachologic effect:
Metabolic agent, has a hypotensive and antiarrhythmic effect, dilates the coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. Contained in many organs and tissues, but most of all - in the skeletal muscles. Improves metabolism and energy supply of tissues. Splitting into ADP and inorganic phosphate, ATP releases a large amount of energy used for muscle contraction, protein synthesis, urea, intermediate metabolic products, etc. Later, the decay products are included in ATP resynthesis. Under the influence of ATP, blood pressure decreases and smooth muscles relax, the conduction of nerve impulses in the autonomic ganglia and the transfer of excitation from n.vagus to the heart improve, myocardial contractility increases. ATP inhibits the automatism of the sinoatrial node and Purkinje fibers (blockade of Ca2+ channels and increased permeability to K+).

Indications:
Supraventricular paroxysmal tachycardia (paroxysm relief). Previously, the drug was used for the following indications (at present, due to low efficacy, the following indications are excluded): muscular dystrophy and atrophy, poliomyelitis, multiple sclerosis, coronary insufficiency, postinfarction cardiomyodystrophy, acute and chronic cardiovascular insufficiency, obliterating diseases of the arteries - "intermittent " lameness, Raynaud's disease, thromboangiitis obliterans (Buerger's disease), hereditary pigmentary retinal degeneration, weakness of labor activity.

Contraindications:
Hypersensitivity, acute myocardial infarction, arterial hypotension, inflammatory lung diseases.

Side effects:
Allergic reactions (itching, skin hyperemia). With the / m administration - headache, tachycardia, increased diuresis, hyperuricemia; with intravenous - nausea, flushing of the skin of the face, headache, weakness.

Dosage and administration:
In / m, in / in or in / a. In the first days of treatment - in / m, 10 mg (1 ml of a 1% solution) 1 time per day, then at the same dose 2 times a day or 20 mg 1 time per day. The course of treatment - 30-40 injections, repeated course - after 1-2 months. For the relief of supraventricular arrhythmias - in / in, 10-20 mg, for 5-6 seconds (the effect occurs after 30-40 seconds), if necessary, repeated administration is possible after 2-3 minutes.

Special instructions:
Do not administer large doses simultaneously with cardiac glycosides.

Interaction:
Cardiac glycosides increase the risk of side effects (including arrhythmogenic effects).

Trifosadenine (sodium adenosine triphosphate) (triphosadenine)

Composition and form of release of the drug

Solution for intravenous administration colorless or slightly yellowish, transparent.

* disodium adenosine triphosphate dihydrate in terms of adenosine triphosphoric acid.

Excipients: anhydrous sodium carbonate - 4.4 mg, - 8 mg, disodium edetate dihydrate - 0.2 mg, propylene glycol - 0.1 mg, water for injection - up to 1 ml.

1 ml - ampoules (5) - packs of cardboard.
1 ml - ampoules (10) - packs of cardboard.
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (1) - cardboard packs.
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (2) - cardboard packs.
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (4) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (5) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (10) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (50) - cardboard packs (for hospitals).
1 ml - ampoules (5) - blister packs made of polyvinyl chloride film (100) - cardboard packs (for hospitals).

pharmachologic effect

Means that improves metabolism and energy supply of tissues. ATP is a natural component of body tissues - it is involved in many metabolic processes. When ATP breaks down into ADP and inorganic phosphate, the energy necessary for muscle contraction and various biochemical processes is released. ATP is involved in the transmission of excitation in adrenergic and cholinergic synapses, facilitates the transfer of excitation from the vagus nerve to the heart. Apparently, ATP is one of the mediators that excite adenosine receptors. Strengthens brain and coronary circulation, promotes increase in peripheral blood circulation.

Trifosadenine is a derivative of adenosine. Adenosine is an agonist of purinergic receptors, the activation of which leads to inhibition of the depolarization of the conduction processes. electrical impulses in the sinus and AV nodes. This effect underlies the antiarrhythmic action of triphosadenine in supraventricular tachycardia. Acts briefly for a few seconds.

Pharmacokinetics

After parenteral administration, it penetrates into the cells of organs, where it is cleaved into adenosine and inorganic phosphate with the release of energy. In the future, the decay products are included in the resynthesis of ATP.

Indications

Muscular dystrophy and atony, poliomyelitis,; retinitis pigmentosa; peripheral vascular disease (intermittent claudication, Raynaud's disease, thromboangiitis obliterans); relief of paroxysms of supraventricular tachycardia, ischemic heart disease; weakness of labor activity.

Contraindications

Acute, arterial hypotension, inflammatory diseases of the lungs, hypersensitivity to triphosadenine.

Tradename drug: Sodium adenosine triphosphate

international generic name(INN): Trifosadenine

Dosage form:


solution for intravenous administration

Composition:


1 ml of solution contains active substance adenosine triphosphoric acid - 10 mg.
Excipients: sodium hydroxide solution 2 M (up to pH 7.0-7.3), water for injection.

Description
Clear colorless or slightly yellowish liquid.

Pharmacotherapeutic group:


metabolic agent

CodeATH:

pharmachologic effect
Sodium adenosine triphosphate (ATP) is a metabolic agent, has an antiarrhythmic effect, also has a hypotensive effect, dilates the coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. Contained in many organs and tissues, but most of all - in the skeletal muscles. Improves metabolism and energy supply of tissues. Due to its splitting into ADP and inorganic phosphate, ATP releases a large amount of energy used for muscle contraction, protein synthesis, urea, metabolic intermediates, etc. Under the influence of ATP, blood pressure decreases and smooth muscles relax, and nerve impulses in the autonomic ganglia improve and transmission of excitation from the vagus nerve to the heart, myocardial contractility increases. After parenteral administration, it penetrates into the cells of organs, where it is cleaved into adenosine and inorganic phosphate with the release of energy. In the future, the cleavage products are included in the resynthesis of ATP. The antiarrhythmic effect is due to the adenosine formed during the breakdown of ATP, which suppresses the automatism of the sinoatrial node and Purkinje fibers (blockade of calcium channels and an increase in permeability to potassium ions).

Indications for use
Relief of paroxysms of supraventricular tachycardia (excluding flicker and / or atrial flutter).

Contraindications
Hypersensitivity, acute myocardial infarction, arterial hypotension, inflammatory lung diseases.

Dosage and administration
The drug is administered intravenously quickly into the central or large peripheral vein 3 mg for 2 seconds under the control of the electrocardiogram and blood pressure; if necessary, after 1-2 minutes, 6 mg of the drug is re-introduced, after 1-2 minutes. 12 mg; the introduction is stopped with the development of atrioventricular blockade at any of the stages of drug administration.

Side effect
Allergic reactions (itching, flushing of the skin), nausea, flushing of the skin of the face, headache, weakness are possible; after stopping the paroxysm of tachycardia, short-term episodes of sinus bradycardia and / or atrioventricular block I-III degree may be observed (ECG control).

Overdose
Due to the short half-life, adverse events quickly disappear. Competitive antagonists are theophylline and other methylxanthines.

Interaction with other drugs
Cardiac glycosides increase the risk of side effects (including arrhythmogenic effects). Dipyridamole enhances the effect; theophylline, caffeine and other methylxanthines - weaken.

special instructions
Do not administer large doses simultaneously with cardiac glycosides.

Release form
1 ml in ampoules. 10 ampoules with a knife for opening ampoules and instructions for use in a cardboard box.

Storage conditions
List B. In a place protected from light, at a temperature of (5 ± 2) ° C. Keep out of the reach of children.

Best before date
1 year.
Do not use after the expiry date stated on the packaging

Terms of dispensing from pharmacies
On prescription

Manufacturer
RUE "Borisov Plant of Medical Preparations", Republic of Belarus, Minsk region, Borisov, st. Chapaev, 64/27.